Testing effectiveness (Phase 2)Ended earlyNCT01034657
What this trial is testing
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)
Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 34